Menu Home About About Us Our Team Publications Platform CAR-γδ T Cell iPSC-γδ NKT Cell Pipeline Manufacturer Investors Contact Us Make An Appointment Advancing "Off-the-shelf” Allogeneic Cellular Immunotherapy for a Broad-spectrum of Cancers Pioneering Stem Cell Research & Therapy Contact Us Seek, See and Destroy ‒ iPSC-γδ NKT Cells Eliminate Cancer Cells! CytoMed's Technologies
CytoMed is translating its patent-pending technologies into gamma delta (γδ) T cell- and natural killer (NK) cell-based "off-the-shelf" immunotherapeutics for a wide range of cancers.
CytoMed also engages in generating induced pluripotent stem cells (iPSCs) and developing them into cellular therapeutics using our proprietary technologies for our customers.